老年人偏头痛
本文综述老年人(定义为60岁及以上)偏头痛的临床特点、诊断治疗复杂性及研究局限。发作性偏头痛患病率在30岁后期达峰后倾向缓解,慢性偏头痛更可能持续至晚年。老年人常有不典型特征和共病,且常被随机对照试验排除,新型药物在该人群的疗效、耐受性和安全性多不确定。
要点
- 发作性偏头痛患病率在30岁后期达峰,此后倾向随年龄增长而缓解;慢性偏头痛更易持续至晚年。
- 老年人偏头痛诊断治疗更复杂,因不典型临床特征和共病概率增加,共病有时限制治疗选择。
- 新型偏头痛药物在老年人中的有效性、耐受性和安全性常不确定,因老年人常被随机对照试验排除或仅占很小比例。
核心结论
- 偏头痛是演变性、有时终生性的障碍;老年人偏头痛的诊断治疗因不典型特征和共病而更复杂。
- 偏头痛随生命周期变化的临床表现在老年人中尚未充分表征,缓解的神经生物学基础仍不清楚。
- 需要认识现有证据的局限及老年人偏头痛常未被满足的临床需求。
研究设计与样本
- 综述;检索范围原文未报告。
主要发现
- 发作性偏头痛患病率在30岁后期个体中达峰,提示此后随年龄增长有缓解倾向。
- 慢性偏头痛更可能持续至晚年。
- 老年人定义为60岁及以上个体。
- 血管、神经元和激素变化可能参与老年人偏头痛的缓解。
- 长期纵向研究可提供信息,可能提示新研究方向并识别新型治疗药物。
关键数值与推荐
- 发作性偏头痛患病率峰值在30岁后期。
- 老年人定义为60岁及以上个体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 偏头痛随生命周期变化的临床表现尚未充分表征。
- 老年人偏头痛缓解的神经生物学基础仍不清楚。
- 新型偏头痛药物在老年人中的有效性、耐受性和安全性常不确定,因老年人常被随机对照试验排除或仅占很小比例。
- 需要认识现有证据的局限及老年人偏头痛常未被满足的临床需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Migraine is an evolving, and sometimes lifelong disorder. The prevalence of episodic migraine peaks among individuals aged in their late 30s, implying a tendency for the disorder to remit with increasing age thereafter, whereas chronic migraine is more likely to persist into later life. Diagnosis and treatment of migraine in older adults, defined as individuals aged 60 years or older, is rendered more complex by increasing probabilities of atypical clinical features and comorbidities, with patients' comorbidities sometimes limiting their therapeutic options. However, the changing clinical presentation of migraine over an individual's lifespan is not well characterised. The neurobiological basis of remission in older adults remains unclear, although vascular, neuronal, and hormonal changes are likely to be involved. Long-term longitudinal studies of individuals with migraine would be particularly informative, with the potential not only to suggest new research directions, but also to lead to the identification of novel therapeutic agents. Although several novel migraine medications are becoming available, their effectiveness, tolerability, and safety often remain uncertain in older adults, who have commonly been excluded from the evaluation of these agents in randomised controlled trials, or who constitute only a small proportion of study populations. There is a need to recognise these limitations in the available evidence, and the specific, and often unmet, clinical needs of older adults with migraine, not least because older adults constitute an increasing proportion of populations worldwide.
引用
- Hugger SS, Do TP, Ashina H, et al. Migraine in older adults. Lancet Neurol. 2023. PMID: 37717587. doi:10.1016/S1474-4422(23)00206-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。